ScreenerHero

VRDN Viridian Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · viridiantherapeutics.com
18.28USD+0.33%Mkt Cap: 2.07B $P/E: —

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. It develops IGF-1R therapies to treat thyroid eye disease (TED), including Veligrotrug, a diff…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap2.07B USD
Enterprise Value1.43B USD
Revenue (TTM)71.13M USD
Gross Profit-253.55M USD
Net Income (TTM)-342.60M USD
Revenue/Share0.74 USD
Last Price18.28 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees252
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.62
PEG—
EV/EBITDA-3.52
EV/Revenue20.04
P/S29.02
P/B3.66
EPS (TTM)-3.25
EPS (Forward)-2.75
52W Range
13.1824% of range34.29
52W High34.29 USD
52W Low13.18 USD
Profitability
Gross Margin0.00%
Oper. Margin-44460.56%
EBITDA Margin0.00%
Profit Margin-483.57%
ROE-47.44%
ROA-38.09%
Growth
Revenue Growth278.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-276.39M USD
CapEx (TTM)495.00K USD
FCF Margin-387.33%
FCF Yield-13.30%
Net Debt-736.80M USD
Net Debt/EBITDA1.82
Balance Sheet
Debt/Equity0.07
Current Ratio16.95
Quick Ratio16.56
Book Value/Sh4.98 USD
Cash/Share8.66 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay DateNov 13, 2020
Splits
Last Split1:15
Split DateNov 13, 2020
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)36.75 USD
Upside (mean)+101.0%
Target Range22.00 USD – 50.00 USD
22.00+101.0% to mean50.00
# Analysts16
Ownership
Shares Out.113.29M
Float100.79M
Insiders0.17%
Institutions126.77%
Short Interest
Short Ratio15.9d
Short % Float17.81%
Short % Out.17.18%
Shares Short19.47M
Short (prev mo.)19.03M
Technical
SMA 5021.95 (-16.7%)
SMA 20022.76 (-19.7%)
Beta1.10
S&P 52W Chg16.45%
Avg Vol (30d)1.68M
Avg Vol (10d)2.01M
Technical Indicators
RSI (14)32.1
MACD-0.8797
MACD Signal-0.5017
MACD Hist.-0.3780
BB Upper23.98 USD
BB Middle20.91 USD
BB Lower17.83 USD
BB Width29.44%
ATR (14)0.9235 USD
Vol Ratio (20d)0.89x